Clinical analysis of 125I seed implantation combined with Apatinib in the treatment of locally advanced lung cancer: a case series

Authors

  • Yiling Feng Department of Oncology, Characteristic Medical Center of Chinese People's Armed Police Force, Tianjin, China
  • Bo Yang Department of Thoracic Surgery, Tianjin First Central Hospital, Tianjin, China
  • Xiaoping Li Tianjin First Central Hospital

DOI:

https://doi.org/10.47391/JPMA.1442

Abstract

Abstract

This clinical analysis of 125I seed implantation combined with Apatinib in the treatment of locally advanced lung cancer with negative driving genes was retrospectively performed on 19 patients in the Department of Thoracic Surgery, Tianjin First Central Hospital, from January 2018 to May 2019. Twelve cases were treated with Apatinib after 125I implantation, while the other seven were treated with 125I implantation only. IL-2R, IL-6 and TNF-? before and after the treatment, imaging changes every two months and related side effects were recorded. After the treatment, IL-2R, IL-6 and TNF-? of all the patients decreased in the first month, which was more obvious in combined therapy patients; the total effective rate in combined therapy patients was significantly higher than the others. There were no fatal complications, and all the side-effects were well tolerated by medical treatment.

Continuous....

Published

2020-10-13

How to Cite

Yiling Feng, Bo Yang, & Li, X. (2020). Clinical analysis of 125I seed implantation combined with Apatinib in the treatment of locally advanced lung cancer: a case series. Journal of the Pakistan Medical Association, 1-11. https://doi.org/10.47391/JPMA.1442

Issue

Section

Case Series